published on 20.04.2018
Albutec supported Europe's largest liver congress (EASL ILC 2018) this year and was represented as an industrial exhibitor with its own stand.
The EASL ILC took place this year from 11 to 15 April at the EXPO site in Paris.
In addition to the industrial exhibition, Albutec was also able to present its latest development to interested experts at a workshop for extracorporeal liver support.
In Albutec's view, the presentation of clinical data from the OPALESCE study by Dr. Jan Stange was of special value. The presented data (see Abstract EASL ILC 2018 Poster) show that the Hepalbin-Cluster12 within the OPAL system improves the albumin binding function (ABF) of plasma albumin in the liver patient.
Albutec GmbH • Schillingallee 68 • 18057 Rostock • Germany Phone: +49-381-12165871 • Fax: +49-381-12165877